Clinical Trials Sponsored by Regimmune Inc.

Total 36069 results

MedImmune LLC

Terminated

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

Cancer | Solid Tumors | CTCL

United States, France, Canada
MedImmune LLC

Completed

Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884

Healthy Volunteers

United States
MedImmune LLC

Completed

A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors. (MEDI-575)

Cancer

United States
MedImmune LLC

Completed

Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis (D2213C00001)

Atopic Dermatitis

United States, Germany, Canada, Australia, Poland, Japan
MedImmune LLC

Completed

Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma

United States, Poland
MedImmune LLC

Completed

To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease

Coronary Artery Disease

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults

Respiratory Syncytial Virus (RSV)

United States
MedImmune LLC

Completed

A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children

Healthy

United States
MedImmune LLC

Terminated

Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)

RSV Infection

United Kingdom
MedImmune LLC

Terminated

A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Bulgaria, Poland, Russian Federation, South Africa, Spain, United Kingdom, Estonia, Hungary, Ukraine, Argentina, Chile, Czechia, Israel, Slovakia, Greece, Germany, Serbia, Colombia, Mexico
MedImmune LLC

Completed

A Study to Assess the Safety of MEDI7836 in Healthy Adults.

Healthy Adults

United Kingdom
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults

Respiratory Syncytial Virus Infections

United States
MedImmune LLC

Completed

A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States, Brazil, Bulgaria, Czech Republic, Korea, Republic of, Mexico, Peru, Hungary, Poland, Romania, Ukraine, Taiwan, India, Colombia
MedImmune LLC

Completed

Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age

Observation Safety

United States
MedImmune LLC

Completed

A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers

Healthy Volunteers

Germany
MedImmune LLC

Completed

Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults (MEDI8852)

Influenza

United States
MedImmune LLC

Completed

A Double-blind, Placebo-controlled, Single-dose Study to Evaluate the PK, IM, and Safety in Japanese Subjects

Healthy Volunteers

United Kingdom
MedImmune LLC

Completed

A Study to Describe Pediatric Influenza Vaccine Coverage

Healthy

United States
MedImmune LLC

Terminated

A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528

Asthma

United States
MedImmune LLC

Completed

Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers

Asthma

United States
MedImmune LLC

Completed

A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma

Asthma

Canada
MedImmune LLC

Completed

A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United Kingdom, South Africa
MedImmune LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children

Motavizumab Administration for a Second Season for RSV Prophylaxis

Chile, Brazil
MedImmune LLC

Terminated

A Study to Evaluate Biomarkers in Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States, Canada
MedImmune LLC

Completed

A Study to Evaluate the Safety of FluMist in Healthy Children and Healthy Adults

Healthy

United States
MedImmune LLC

Completed

A Study to Assess Selected Biomarkers in Subjects Requiring Daily Inhaled Corticosteroids for Persistent Asthma

Asthma

United States, Canada
MedImmune LLC

Completed

A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma

Asthma

United States, Canada
MedImmune LLC

Completed

A Study of the Inflammatory Pathways Associated With Chronic Obstructive Pulmonary Disease Exacerbations

Chronic Obstructive Pulmonary Disease

Ireland
MedImmune LLC

Withdrawn

A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants

Wheezing
MedImmune LLC

Completed

A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus

Lupus

Brazil, United States, Chile, Argentina
MedImmune LLC

Completed

A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease

Congenital Heart Disease

United States, Spain, United Kingdom, Canada, Belgium, Germany, Israel, Austria, Poland, Russian Federation, Sweden, Lebanon, France, Czech Republic, Hungary, Denmark, Bulgaria
MedImmune LLC

Terminated

A Phase 1/2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to < 12 Months of Age

Healthy

United States
MedImmune LLC

Terminated

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)

Lymphoma

United States, Poland
MedImmune LLC

Completed

A Clinical Study to Assess the Safety of a New Influenza Vaccine

Healthy

United States
MedImmune LLC

Completed

A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine (MI-MA205)

Healthy

United States
MedImmune LLC

Completed

A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine (MI-MA182)

Influenza

United States
MedImmune LLC

Withdrawn

A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer

Breast Cancer

United States
MedImmune LLC

Completed

Respiratory Events Among Premature Infants

Respiratory Syncytial Virus

United States
MedImmune LLC

Completed

Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis

Psoriasis

United States, Canada
MedImmune LLC

Completed

Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors

Cancer

France
MedImmune LLC

Completed

Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Leukemia

United States, Israel
MedImmune LLC

Completed

Study of MEDI 507 in the Treatment of Pediatric Patients (Pediatric GvHD)

Graft Versus Host Disease

United States
MedImmune LLC

Completed

A Sequential Dose-Escalation Study in Subjects With Mild Asthma

Asthma

United States
MedImmune LLC

Completed

Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program

Influenza

United States
MedImmune LLC

Withdrawn

A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin
MedImmune LLC

Completed

Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer

Cancer

United States
MedImmune LLC

Completed

MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer

Prostate Cancer

United States, Belgium, Israel, Russian Federation, Canada, Hungary, Poland
MedImmune LLC

Completed

A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis

Plaque Psoriasis

United States, Canada
MedImmune LLC

Completed

Study To Evaluate the Safety of Bivalent Vaccine

Healthy

United States
MedImmune LLC

Recruiting

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

United States, Spain, France, Australia

3

Subscribe